Treatment of heart failure with fosinopril: An angiotensin converting enzyme inhibitor with a dual and compensatory route of excretion

Giuseppe Mancia, Cristina Giannattasio, Guido Grassi

Research output: Contribution to journalArticlepeer-review

Abstract

Congestive heart failure (CHF) is one of the most common and clinically important cardiovascular diseases. This pathologic state is characterized not only by well-defined hemodynamic alterations, but also by complex abnormalities involving the sympathetic nervous system, the renin-angiotensin system, and other hormones involved in cardiovascular homeostasis. In addition, there is an abnormality in the homeostatic cardiovascular control exerted by arterial baroreceptors and the viscoelastic properties of medium- size arteries are altered, causing a reduction in arterial compliance. All of these abnormalities can be favorably affected by angiotensin converting enzyme (ACE) inhibitors, which have been shown to improve not only the hemodynamic and neurohumoral profiles of CHF, but also patient survival. CHF is accompanied with a decline or some sort of effect on renal function. An ACE inhibitor with a dual route of excretion, such as fosinopril, may be especially useful in treating patients with CHF.

Original languageEnglish
JournalAmerican Journal of Hypertension
Volume10
Issue number10 II SUPPL.
Publication statusPublished - Oct 1997

Keywords

  • Angiotensin converting enzyme inhibitors
  • Arterial compliance
  • Congestive heart failure
  • Fosinopril
  • Reflex control of circulation
  • Sympathetic activity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Treatment of heart failure with fosinopril: An angiotensin converting enzyme inhibitor with a dual and compensatory route of excretion'. Together they form a unique fingerprint.

Cite this